1
|
Muraoka S, Jedrychowski MP, Iwahara N, Abdullah M, Onos KD, Keezer KJ, Hu J, Ikezu S, Howell GR, Gygi SP, Ikezu T. Enrichment of Neurodegenerative Microglia Signature in Brain-Derived Extracellular Vesicles Isolated from Alzheimer's Disease Mouse Models. J Proteome Res 2021; 20:1733-1743. [PMID: 33534581 PMCID: PMC7944570 DOI: 10.1021/acs.jproteome.0c00934] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
![]()
Extracellular vesicles
(EVs) are secreted by any neural cells in
the central nervous system for molecular clearance, cellular communications,
and disease spread in multiple neurodegenerative diseases, including
Alzheimer’s disease (AD), although their exact molecular mechanism
is poorly understood. We hypothesize that high-resolution proteomic
profiling of EVs separated from animal models of AD would determine
the composition of EV contents and their cellular origin. Here, we
examined recently developed transgenic mice (CAST.APP/PS1), which express familial AD-linked mutations of amyloid precursor
protein (APP) and presenilin-1 (PS1) in the CAST/EiJ mouse strain and develop hippocampal neurodegeneration.
Quantitative proteomics analysis of EVs separated from CAST.APP/PS1 and age-matched control mice by tandem mass tag-mass
spectrometry identified a total of 3444 unique proteins, which are
enriched in neuron-, astrocyte-, oligodendrocyte-, and microglia-specific
molecules. CAST.APP/PS1-derived EVs show significant
enrichment of Psen1, APP, and Itgax and reduction of Wdr61, Pmpca,
Aldh1a2, Calu, Anp32b, Actn4, and Ndufv2 compared to WT-derived EVs,
suggesting the involvement of Aβ-processing complex and disease-associated/neurodegenerative
microglia (DAM/MGnD) in EV secretion. In addition, Itgax and Apoe,
DAM/MGnD markers, in EVs show a positive correlation with Itgax and Apoe mRNA expression from brain
tissue in CAST.APP/PS1 mice. These datasets indicate
the significant contribution of Aβ plaque and neurodegeneration-induced
DAM/MGnD microglia for EV secretion in CAST.APP/PS1 mice and shed light on understanding AD pathogenesis.
Collapse
Affiliation(s)
- Satoshi Muraoka
- Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts 02118, United States
| | - Mark P Jedrychowski
- Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02118, United States
| | - Naotoshi Iwahara
- Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts 02118, United States
| | - Mohammad Abdullah
- Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts 02118, United States
| | - Kristen D Onos
- The Jackson Laboratory, Bar Harbor, Maine 04609-1523, United States
| | - Kelly J Keezer
- The Jackson Laboratory, Bar Harbor, Maine 04609-1523, United States
| | - Jianqiao Hu
- Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts 02118, United States
| | - Seiko Ikezu
- Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts 02118, United States
| | - Gareth R Howell
- The Jackson Laboratory, Bar Harbor, Maine 04609-1523, United States
| | - Steven P Gygi
- Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02118, United States
| | - Tsuneya Ikezu
- Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts 02118, United States.,Department of Neurology, Alzheimer's Disease Center, Boston University School of Medicine, Boston, Massachusetts 02118, United States.,Center for Systems Neuroscience, Boston University, Boston, Massachusetts 02118, United States.,Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida 32224, United States
| |
Collapse
|
2
|
Abstract
The histone deacetylase inhibitor, trichostatin A, is used to treat Alzheimer's disease and can improve learning and memory but its underlying mechanism of action is unknown. To determine whether the therapeutic effect of trichostatin A on Alzheimer's disease is associated with the nuclear factor erythroid 2-related factor 2 (Nrf2) and Kelch-like epichlorohydrin-related protein-1 (Keap1) signaling pathway, amyloid β-peptide 25-35 (Aβ25-35) was used to induce Alzheimer's disease-like pathological changes in SH-SY5Y neuroblastoma cells. Cells were then treated with trichostatin A. The effects of trichostatin A on the expression of Keap1 and Nrf2 were detected by real-time quantitative polymerase chain reaction, western blot assays and immunofluorescence. Total antioxidant capacity and autophagy activity were evaluated by total antioxidant capacity assay kit and light chain 3-I/II levels, respectively. We found that trichostatin A increased cell viability and Nrf2 expression, and decreased Keap1 expression in SH-SY5Y cells. Furthermore, trichostatin A increased the expression of Nrf2-related target genes, such as superoxide dismutase, NAD(P)H quinone dehydrogenase 1 and glutathione S-transferase, thereby increasing the total antioxidant capacity of SH-SY5Y cells and inhibiting amyloid β-peptide-induced autophagy. Knockdown of Keap1 in SH-SY5Y cells further increased trichostatin A-induced Nrf2 expression. These results indicate that the therapeutic effect of trichostatin A on Alzheimer's disease is associated with the Keap1-Nrf2 pathway. The mechanism for this action may be that trichostatin A increases cell viability and the antioxidant capacity of SH-SY5Y cells by alleviating Keap1-mediated inhibition Nrf2 signaling, thereby alleviating amyloid β-peptide-induced cell damage.
Collapse
Affiliation(s)
- Li-Hua Li
- College of Medicine, Jishou University, Jishou, Hunan Province, China
| | - Wen-Na Peng
- Department of Rehabilitation, Second Xiangya Hospital, Changsha, Hunan Province, China
| | - Yu Deng
- College of Medicine, Jishou University, Jishou, Hunan Province, China
| | - Jing-Jing Li
- College of Medicine, Jishou University, Jishou, Hunan Province, China
| | - Xiang-Rong Tian
- College of Biology and Environmental Science, Jishou University, Jishou, Hunan Province, China
| |
Collapse
|
3
|
Bernabeu-Zornoza A, Coronel R, Palmer C, Monteagudo M, Zambrano A, Liste I. Physiological and pathological effects of amyloid-β species in neural stem cell biology. Neural Regen Res 2019; 14:2035-2042. [PMID: 31397330 PMCID: PMC6788229 DOI: 10.4103/1673-5374.262571] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2019] [Accepted: 04/03/2019] [Indexed: 12/17/2022] Open
Abstract
Although amyloid-β peptide is considered neurotoxic, it may mediate several physiological processes during embryonic development and in the adult brain. The pathological function of amyloid-β peptide has been extensively studied due to its implication in Alzheimer's disease, but its physiological function remains poorly understood. Amyloid-β peptide can be detected in non-aggregated (monomeric) and aggregated (oligomeric and fibrillary) forms. Each form has different cytotoxic and/or physiological properties, so amyloid-β peptide and its role in Alzheimer's disease need to be studied further. Neural stem cells and neural precursor cells are good tools for the study on neurodegenerative diseases and can provide future therapeutic applications in diseases such as Alzheimer's disease. In this review, we provide an outline of the effects of amyloid-β peptide, in monomeric and aggregated forms, on the biology of neural stem cells/neural precursor cells, and discuss the controversies. We also describe the possible molecular targets that could be implicated in these effects, especially GSK3β. A better understanding of amyloid-β peptide (both physiological and pathological), and the signaling pathways involved are essential to advance the field of Alzheimer's disease.
Collapse
Affiliation(s)
- Adela Bernabeu-Zornoza
- Unidad de Regeneración Neural, Unidad Funcional de Investigación de Enfermedades Crónicas. Instituto de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain
| | - Raquel Coronel
- Unidad de Regeneración Neural, Unidad Funcional de Investigación de Enfermedades Crónicas. Instituto de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain
| | - Charlotte Palmer
- Unidad de Regeneración Neural, Unidad Funcional de Investigación de Enfermedades Crónicas. Instituto de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain
| | - María Monteagudo
- Unidad de Regeneración Neural, Unidad Funcional de Investigación de Enfermedades Crónicas. Instituto de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain
| | - Alberto Zambrano
- Unidad de Regeneración Neural, Unidad Funcional de Investigación de Enfermedades Crónicas. Instituto de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain
| | - Isabel Liste
- Unidad de Regeneración Neural, Unidad Funcional de Investigación de Enfermedades Crónicas. Instituto de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain
| |
Collapse
|